Targeting FGFR, Ephrins, Mer, MET, and PDGFR-α in Non-small Cell Lung Cancer

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages S1797-S1798

  Riess, Jonathan W ^a   Neal, Joel W ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPHRIN; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MERTK PROTEIN, HUMAN; MET PROTEIN, HUMAN; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; EPHRINS; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 84857079469     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000407562.07029.52     Document Type: Article

References (13)

1. Marek, L, Ware, KE, Fritzsche, A, et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 75 (2009), 196–207.
2. Weiss, J, Sos, ML, Seidel, D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Transl Med, 2, 2010, 62ra93.
3. Bai, A, Meetze, K, Vo, NY, et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res 70 (2010), 7630–7639.
4. Liu, L, Shi, H, Liu, Y, et al. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. Mol Cancer Ther 10 (2011), 518–530.
5. Kinch, MS, Moore, MB, Harpole, DH Jr, Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9 (2003), 613–618.
6. Faoro, L, Singleton, PA, Cervantes, GM, et al. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem 285 (2010), 18575–18585.
7. Chang, Q, Jorgensen, C, Pawson, T, et al. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 99 (2008), 1074–1082.
8. Lee, JW, Stone, RL, Lee, SJ, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res 16 (2010), 2562–2570.
9. Wesa, AK, Herrem, CJ, Mandic, M, et al. Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. J Immunol 181 (2008), 7721–7727.
10. Gobin, AM, Moon, JJ, West, JL, EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells. Int J Nanomed 3 (2008), 351–358.
11. Noberini, R, Koolpe, M, Peddibhotla, S, et al. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem 283 (2008), 29461–29472.
12. Linger, RM, Keating, AK, Earp, HS, et al. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets 14 (2010), 1073–1090.
13. McDermott, U, Ames, RY, Iafrate, AJ, et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res 69 (2009), 3937–3946.